New Drugs for Myeloma

Richardson, Paul G.; Mitsiades, Constantine S.; Schlossman, Robert; Munshi, Nikhil C.; Anderson, Kenneth C.

doi:10.1634/theoncologist.12-6-664

Cited by 148 publications

(108 citation statements)

References 153 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…32 This is being explored as a possible alternative to adding a cytotoxic drug or an established novel agent to prior active regimens. Currently, various new dexamethasone ϩ lenalidomideor dexamethasone ϩ bortezomib-based 3-or 4-drug combinations with new agents such as carfilzomib, 33,34 panobinostat, 35 vorinostat, 27,36 and elotuzumab 37 are being investigated in patients with relapsed/refractory MM and newly diagnosed MM, with promising results to date.…”

Section: Discussionmentioning

confidence: 99%

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

Jakubowiak

Griffith

Reece

et al. 2011

Blood

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

Jakubowiak

Griffith

Reece

et al. 2011

Blood

Self Cite

View full text Add to dashboard Cite

“…Other lenalidomide-based regimens are under investigation for the treatment of relapsed or refractory MM such as lenalidomide plus doxorubicin and dexamethasone (RAD) or lenalidomide plus pegylated liposomal doxorubicin-vincristindexamethasone (R-Dvd) (41). In a phase I ⁄ II trial evaluating RAD regimen, 26 patients out of 31 (84%) achieved a partial response including one confirmed CR with an acceptable toxicity profile (42).…”

Section: Newly Diagnosed MM Patients Eligible For Hdtmentioning

confidence: 99%

Lenalidomide in the treatment of multiple myeloma: a review

2008

View full text Add to dashboard Cite

Lenalidomide is an immunomodulatory drug derived from thalidomide. It was developed to maximize the anti-inflammatory and anti-neoplasic properties of thalidomide and to reduce its toxicity. The molecular mechanism of action of lenalidomide is unclear, but its therapeutic activity is mainly due to its well defined antiinflammatory, immunomodulatory, anti-proliferative and anti-angiogenic properties. In relapsed or refractory multiple myeloma (MM), lenalidomide, combined with standard dose dexamethasone, is superior to dexamethasone alone in terms of time to progression, response rate and overall survival. The most commonly reported adverse events include haematological toxicity with manageable neutropenia and thrombopenia. Lenalidomide does not trigger the limiting toxicities of thalidomide: somnolence, neuropathy and constipation. Lenalidomide, in combination with dexamethasone, is indicated for the treatment of MM patients who have received at least one prior therapy and is administered orally at the dose of 25 mg q.d. for 21 days of 28-day cycles. The drug is being investigated for the treatment of newly diagnosed MM. In this review, we summarize the pharmacokinetic, pharmacodynamic and clinical trial data on lenalidomide.

show abstract

“…MM is an incurable disease, although patient survival has increased with the availability of novel agents ( (Mahindra et al 2010;Minnema et al 2010). Both multiple myeloma and its therapies often affect the renal, immune, skeletal, hematologic, and nervous systems (Minnema et al 2010;Richardson et al 2007;Elouni et al 2010). The resulting organ dysfunctions often impair the life quality of affected patients, complicate and limit subsequent therapies, and may result in significant mortality.…”

Section: Introductionmentioning

confidence: 99%

New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma

Kozanoğlu

Yandım

Çinçin

et al. 2012

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose Propranolol, a non-selective b-adrenergic receptor blocker, has been used for the treatment of the patients with hypertension for more than 50 years. There are several in vitro and in vivo evidences that b-adrenergic receptor antagonists inhibit proliferation and angiogenesis and also increase apoptosis in breast, skin, and colon cancers. The aim of this study was to investigate the cytotoxic and apoptotic effects of propranolol and the genes involved in propranololinduced apoptosis in multiple myeloma cells. Methods Time-dependent antiproliferation and apoptotic effects of propranolol were subsequently determined by MTT cell proliferation assay, changes in caspase-3 activity, loss of mitochondrial membrane potential (MMP), and also the localization of phosphatidylserine in the plasma membrane. Changes in expression levels of NF-JB pathway were examined by qRT-PCR array.Results IC50 values of propranolol on U266 cells were calculated as 141, 100, and 75 lM after 24-, 48-, and 72-h propranolol exposure, respectively. There were significant increases in caspase-3 activity, loss of MMP, and increases in apoptotic cell population in response to propranolol in U266 cells in a time-and dose-dependent manner. There were increases in expression levels of BCL10, TRAF family members, interleukins, TLR1-4, TNFRSF10B, NFjB, and the inhibitors of NF-jB genes, and significant decreases in expression levels of Bcl-2 in response to propranolol treatment were observed. Conclusion These results revealed that propranolol has antiproliferative and apoptotic effects on multiple myeloma cells. Being supported with in vivo analyses, propranolol can be a good and economical way to treat multiple myeloma patients.

show abstract

New Drugs for Myeloma

Cited by 148 publications

References 153 publications

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

Lenalidomide in the treatment of multiple myeloma: a review

New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma

Contact Info

Product

Resources

About